BACKGROUND AND PURPOSE: Concomitant chemoradiation is a promising therapy for the treatment of locoregionally advanced head and neck carcinoma. The purpose of this study was to prospectively evaluate early changes in primary tumor perfusion parameters during concomitant cisplatin-based chemoradiotherapy of locoregionally advanced SCCHN and to evaluate their predictive value for response of the primary tumor to therapy. MATERIALS AND METHODS: Twenty patients with locoregionally advanced SCCHN underwent perfusion CT scans before therapy and after completion of 40 Gy and 70 Gy of chemoradiotherapy. BF, BV, MTT, and PS of primary tumors were quantified. Differences in perfusion and tumor volume values during the therapy as well as between responders and nonresponders were analyzed, and ROC curves were used to assess predictive value of the baseline and follow-up functional parameters. RESULTS: The tumor volumes at 40 Gy and at 70 Gy were significantly lower compared with baseline values (P = .014 and P = .007). In the 6 nonresponders, measurements after 40 Gy showed a nonsignificant trend of increased BF, BV, and PS values compared with the baseline values (P = .06). In 14 responders, a significant reduction of BF values was recorded after 40 Gy (P = .04) and after 70 Gy (P = .01). In responders, BV values showed a reduction after 40 Gy followed by a plateau after 70 Gy (P = .04), whereas in nonresponders there was a nonsignificant elevation of the BV. Baseline BV predicted short-term tumor response with a sensitivity of 60% and specificity of 100% (P = .01). After completion of 40 Gy of concomitant chemoradiation BV was a more significant predictor than were BF and MTT. CONCLUSIONS: The results suggest that in advanced SCCHN the perfusion CT monitoring might be of predictive value for identifying tumors that may respond to cisplatin-based chemoradiotherapy.
BACKGROUND AND PURPOSE: Concomitant chemoradiation is a promising therapy for the treatment of locoregionally advanced head and neck carcinoma. The purpose of this study was to prospectively evaluate early changes in primary tumor perfusion parameters during concomitant cisplatin-based chemoradiotherapy of locoregionally advanced SCCHN and to evaluate their predictive value for response of the primary tumor to therapy. MATERIALS AND METHODS: Twenty patients with locoregionally advanced SCCHN underwent perfusion CT scans before therapy and after completion of 40 Gy and 70 Gy of chemoradiotherapy. BF, BV, MTT, and PS of primary tumors were quantified. Differences in perfusion and tumor volume values during the therapy as well as between responders and nonresponders were analyzed, and ROC curves were used to assess predictive value of the baseline and follow-up functional parameters. RESULTS: The tumor volumes at 40 Gy and at 70 Gy were significantly lower compared with baseline values (P = .014 and P = .007). In the 6 nonresponders, measurements after 40 Gy showed a nonsignificant trend of increased BF, BV, and PS values compared with the baseline values (P = .06). In 14 responders, a significant reduction of BF values was recorded after 40 Gy (P = .04) and after 70 Gy (P = .01). In responders, BV values showed a reduction after 40 Gy followed by a plateau after 70 Gy (P = .04), whereas in nonresponders there was a nonsignificant elevation of the BV. Baseline BV predicted short-term tumor response with a sensitivity of 60% and specificity of 100% (P = .01). After completion of 40 Gy of concomitant chemoradiation BV was a more significant predictor than were BF and MTT. CONCLUSIONS: The results suggest that in advanced SCCHN the perfusion CT monitoring might be of predictive value for identifying tumors that may respond to cisplatin-based chemoradiotherapy.
Authors: J Bourhis; G Calais; M Lapeyre; J Tortochaux; M Alfonsi; C Sire; E Bardet; M Rives; P Bergerot; B Rhein; B Desprez Journal: Semin Oncol Date: 2004-12 Impact factor: 4.929
Authors: Vinay K Gupta; Nora T Jaskowiak; Michael A Beckett; Helena J Mauceri; Jeremy Grunstein; Randall S Johnson; Douglas A Calvin; Edwardine Nodzenski; Marija Pejovic; Donald W Kufe; Mitchell C Posner; Ralph R Weichselbaum Journal: Cancer J Date: 2002 Jan-Feb Impact factor: 3.360
Authors: Patrick Veit-Haibach; Daniel Schmid; Klaus Strobel; Jan D Soyka; Niklaus G Schaefer; Stephan K Haerle; Gerhard Huber; Gabriele Studer; Burkhardt Seifert; Thomas F Hany Journal: Eur Radiol Date: 2012-07-08 Impact factor: 5.315
Authors: M T Truong; N Saito; A Ozonoff; J Wang; R Lee; M M Qureshi; S Jalisi; O Sakai Journal: AJNR Am J Neuroradiol Date: 2011-07-14 Impact factor: 3.825
Authors: Thomas Hauser; Marco Essig; Alexandra Jensen; Lars Gerigk; Frederik Bernd Laun; Marc Münter; Dirk Simon; Bram Stieltjes Journal: Neuroradiology Date: 2013-02-17 Impact factor: 2.804
Authors: Minh Tam Truong; Richard Lee; Naoko Saito; Muhammad M Qureshi; Al Ozonoff; Paul B Romesser; Jimmy Wang; Osamu Sakai Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-12 Impact factor: 7.038
Authors: N L Hoefling; J B McHugh; E Light; B Kumar; H Walline; M Prince; C Bradford; T E Carey; S K Mukherji Journal: AJNR Am J Neuroradiol Date: 2013-01-31 Impact factor: 3.825